Latest Pitavastatin Stories
INDIANAPOLIS and MONTGOMERY, Ala., Dec. 23 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S.
BARCELONA, Spain, Sept. 2 /PRNewswire/ -- LIVALO (pitavastatin) may have the potential for fewer drug-drug interactions, versus other statins, as evidenced by a new study that evaluated the effects of itraconazole, an antifungal medication, on the pharmacokinetics of LIVALO in healthy volunteers.
MONTGOMERY, Ala. and RALEIGH, N.C., Aug. 3 /PRNewswire/ -- Kowa Research Institute (KRI) based in Raleigh, NC and Kowa Pharmaceuticals America, Inc. (KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U.S.
Study shows Kowa's novel synthetic statin is safe and well tolerated in combination with warfarin BOSTON, June 15 /PRNewswire/ -- New data presented today showed that pitavastatin may provide a new treatment option for patients with dyslipidemia and complex issues, such as those on multiple medications, as evidenced by a study supporting pitavastatin's potential for low drug-drug interaction.
Italy-based pharmaceutical company Recordati has signed a new agreement with Kowa Pharmaceutical Europe, a subsidiary of the Japanese pharmaceutical company Kowa Co, for the marketing and sales of pitavastatin in France, Spain, Portugal, Greece, Ireland, Cyprus, Turkey, Russia and CIS countries, as well as in Italy.
Kowa Company, a privately-held company headquartered in Nagoya, Japan, has acquired ProEthic Pharmaceuticals, a specialty pharmaceutical company based in Montgomery, Alabama.
NAGOYA, Japan and MONTGOMERY, Ala., Aug. 4 /PRNewswire/ -- Kowa Company, Ltd., a privately-held company headquartered in Nagoya, Japan, today announced the acquisition of ProEthic Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company based in Montgomery, Alabama.
- To swell, as grain or wood with water.